Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Anhui Cancer Hospital, Hefei, Anhui, China
Contact: Study coordinator (Bairong Xia, MD) · xiabairong9999@126.com · 18604516165
Contact: Study coordinator (Wenjing Jiang) · jiangwenjing928@126.com · 13965145956
Contact: Principal Investigator (Bairong Xia, Doctor)
Wenjing Jiang (Sub-investigator)

Study leads

Bairong Xia, Doctor
Study Chair
Anhui Provincial Cancer Hospital
Wenjing Jiang
Study Director
Anhui Provincial Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Palo Alto, United States

Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer

Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Hefei, China

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Maywood, United States

A Study of NX-1607 in Adults With Advanced Malignancies

Ovarian Cancer, Epithelial · Gastric Cancer · GastroEsophageal Junction (GEJ) Cancer

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Los Angeles, United States